Patients with leukemia relapsing after allogeneic hematopoietic SCT have a dismal prognosis. A second SCT offers a further opportunity for cure, but has a high rate of treatment failure. To determine the utility of this option, we analyzed 59 consecutive patients relapsing after a myeloablative HLA-matched sibling T cell-depleted (TCD) SCT. Twenty-five patients (13 relapsing within 6 months and 12 relapsing between 6 and 170 months after the first SCT) received a T-replete second SCT. Thirty-eight patients relapsing early had a shorter survival than the 21 patients relapsing later (median 96 vs 298 days, P ¼ 0.0002). In patients relapsing early, the second SCT did not improve OS compared with patients receiving non-SCT treatments (median survival 109 vs 80 days, P ¼ 0.41). In patients relapsing late, despite an early trend in favor of second SCT, survival was comparable for patients receiving a second SCT compared with non retransplanted patients (median survival 363.5 vs 162 days, P ¼ 0.49). Disappointingly, our results do not demonstrate an important survival benefit for a second T-replete allogeneic SCT to treat relapse following a TCD SCT.
INTRODUCTION
Leukemic relapse is the single biggest cause of treatment failure after hematopoietic SCT for hematological malignancies, and its management remains largely unsuccessful. 1 Patients relapsing with acute leukemia within 6 months of SCT have a 1-year survival of o20%. 2, 3 In comparison, later relapse of acute leukemia after SCT carries a better prognosis, but is still plagued by a high mortality from progressive disease. 4 Consequently, no standard approach exists for management of relapsed disease after SCT. Typically, most patients will receive chemotherapy and/or a DLI, whereas others may only be offered palliative treatment. [5] [6] [7] [8] Selected patients with a good performance status, in whom some disease control is achieved, may receive a second SCT. However, a second SCT is not without risk. Offering a second opportunity for cure logically requires either intensification of the conditioning regimen or enhancement of the GVL effect, which can be achieved by selecting an alternative donor or by promoting a more rapid and complete immune reconstitution. 1, 9 At our institution, we offered a second SCT to selected patients deemed fit enough and with sufficient disease control to survive the procedure without early death from disease progression or treatment-related mortality. In the setting of myeloablative T cell-depleted (TCD) SCT, we sought to augment the GVL effect with a T cell-replete second transplant and reduced immune suppression. Here, we describe our single institute experience of T cell-replete, reduced intensity and second allogeneic SCT from the original donor in 25 patients drawn from a cohort of 59 patients, who relapsed after a matched sibling TCD SCT.
MATERIALS AND METHODS Patients
Between 1997 and 2011, 220 consecutive patients with a hematological malignancy underwent a myeloablative TCD SCT from an HLA-identical sibling on National Heart, Lung and Blood Institute (NHLBI) institutional review board-approved protocols. Patients and donors provided written informed consent before enrolling in the transplantation protocols.
First transplant
All patients received a TCD G-CSF-mobilized PBSC transplant. G-CSF was administered to all donors at a targeted dose of 10-12 mg/kg of body weight subcutaneously for 5 consecutive days prior to collection. The conditioning regimen consisted of 1200 or 1360 cGy TBI, CY (120 mg/ kg over 2 days), with or without fludarabine (125 mg/m 2 over 5 days). Depletion of T cells from the SCT products was accomplished by selection of CD34 þ cells using either the CellPro system (CellPro Inc, Bothel, WA, USA), Isolex system (Nexell Therapeutics Inc, Irvine, CA, USA) or the Miltenyi CliniMacs system (MiltenyiBiotec Inc, Auburn, CA, USA). On the day of SCT, all patients received this enriched CD34 þ stem cell product with a target dose of 5 Â 10 6 CD34 þ cells/kg, accompanied by a predetermined, protocol-specific dose of 0.2-1 Â 10 5 T cells/kg that was obtained by supplementing the final product with T cells from the original unmanipulated PBSC component. All patients received low-dose CSA (target plasma level, 100-200 mcg/L), starting on day À 4 per protocol. In the absence of significant acute GVHD (grade 41), a DLI (1 Â 10 7 CD3 þ cells/kg) was administered between days 45 and 100 after transplantation. Standard prophylaxis against infection included fluconazole and trimethoprim/sulfamethoxazole, which were administered for at least 6 months after transplantation, and weekly surveillance was performed for CMV antigenemia, as described previously. 10, 11 Second transplant Second transplant regimens are detailed in Table 2 . GVHD prophylaxis consisted of CYA alone (target plasma level, 100-200 mcg/L). Standard prophylaxis against infection and virus surveillance are the same as for the first transplant.
Definition of clinical terms
OS was calculated from the interval between the date of transplantation and death, or the last follow-up visit. Relapsed disease for acute leukemia, myelodysplastic syndrome (MDS), CLL, multiple myeloma and non-Hodgkin's lymphoma was defined by morphologic or cytogenetic evidence, either in peripheral blood or in BM.
Statistical analysis
Survival analysis for time-to-event data was used to analyze the effects of baseline risk factors' relapse and OS. For relapse, patients who did not relapse before death or by the end of the study were treated as censored. For OS, patients who were alive by the end of the study were treated as censored. Survival was measured from time of relapse after the first SCT to the last contact date or death. Effects of the baseline risk factors relapse and OS were evaluated using the univariate Cox proportional hazard models. Kruskal-Wallis test was used for the treatment of non-transplanted patients. The overall effects of the risk factors were evaluated using the log-rank P-values, and effects of the individual risk factors were evaluated using P-values based on the two-sided t-tests, with 0.05 significance level. Statistical analyses were performed with SPSS 15.0 (IBM SPSS, Armonk, NY, USA) and Prism 5 (GraphPad Software, San Diego, CA, USA) software.
RESULTS

Patient characteristics
General patient characteristics after first SCT are shown in Tables 1a and b. Fifty-nine patients relapsed with cytogenetic or morphological evidence of disease recurrence after their first SCT. Relapses occurred in 31 AML/MDS, 17 ALL, 4 B-cell malignancies (2 CLL, 1 non-Hodgkin's lymphoma and 1 multiple myeloma), 6 CML-blast phase and 1 CML-accelerated phase (molecular relapses in CML patients were not included in this study, and no chronic-phase CML patient had a hematological relapse). The median age at the time of first SCT for the 30 male and 29 female subjects that relapsed was 36 (range 9-66) years. Thirty-eight patients relapsed within 6 months (early relapse) at a median of 85 days and 21 patients relapsed after 6 months (late relapse) at a median of 465 days after their first transplant. Patient characteristics of SCT recipients vs other treatments did not show significant differences in gender, age, disease status and risk classification at the first SCT, Karnofsky performance status and days of relapse post first SCT in both early and relapse groups. All of our patients were from other institutions or overseas. As a result, cytogenetics were not always available, limiting a full description of the kinetics of the disease and chemorefractoriness.
Second transplant characteristics
Characteristics of the second transplant procedures are shown in Table 2 . A second T-replete SCT from the original donor using a reduced-intensity conditioning regimen was performed in 25 patients: 13/38 early relapses and 12/21 late relapses. The median number of CD34 þ cells infused was 5.76 Â 10 6 cells/kg. Nineteen of the 25 patients received myeloablative conditioning (MAC) with either BU or melphalan, and six received a non-MAC specific to their disease. There was no statistically significant difference in survival outcome in patients who received MAC or non-MAC SCT (median 211 vs 195 days, P ¼ 0.36) (see Figure 1 ).
Prior to second transplant, one patient relapsing early and three relapsing late achieved CR (two CR and one CRi) after chemotherapy alone or in combination with DLI. However, no survival benefit of obtaining a remission prior to the second hematopoietic SCT was noted (P ¼ 0.55, data not shown).
Non-transplant treatment
The treatment for patients not receiving a second SCT is summarized in Table 3 . Of these 34 patients (25 early and 9 late relapse), 9 received chemotherapy with intent to obtain remission in combination with DLI, 6 received chemotherapy alone, 10 received DLI alone and 9 received palliative chemotherapy or hospice care only. In early-relapsed patients, DLI, were given more frequently than those given a second SCT (P ¼ 0.02). Otherwise, there were no differences regarding treatment options between patients who received or did not receive a second transplant in either early or late-relapse groups. Amongst the non-transplant recipients, no treatment emerged as superior for OS (P ¼ 0.19).
Relapse and OS
The distribution of hematological disease type and OS for patients relapsing after the first SCT is shown in Figure 2 . The OS for early vs late relapse after SCT is shown in Figure 3 . Patients experiencing an early relapse included AML/MDS (50%), ALL (32%), CML-blast phase (13%) and B-cell malignancies (non-Hodgkin's lymphoma and multiple myeloma 5%). Patients experiencing a late relapse included AML/MDS (57%), ALL (24%), CML-blast-or accelerated phase (9%) and B-cell malignancies (CLL 10%). Patients relapsing late had a longer OS compared with patients relapsing early (P ¼ 0.0002). No patient relapsing early after the first SCT survived beyond 1 year following relapse, although the probability of 1-year survival for patients with a late relapse was 33% (hazard ratio ¼ 2.97, 95% confidence interval 1.683-5.241 P ¼ 0.0002). At 3 years after relapse, the actuarial survival was 0 for early-relapsed patients (with or without a second SCT). In contrast, the Kaplan-Meier estimate of actuarial survival for late-relapsed Among the 21 patients relapsing late not receiving SCT, one patient with CLL was a long-term survivor at a median follow-up of 6.3 years, whereas two of the 12 transplanted patients (with AML and MDS RAEB2) were long-term survivors beyond 5 years. In 13 early-relapsed patients receiving second HSCT, the cause of treatment failure was relapse in all but two patients (one death from grade IV gastrointestinal GVHD and one from severe hepatic veno-occlusive disease). Four of the 13 patients developed acute GVHD, and no survival benefit was noted from acute GVHD in these patients (P ¼ 0.5041, see Supplementary Figure) . In contrast, in the 12 patients relapsing late after SCT, there was a 58% probability of dying from relapse and a 25% probability of non-relapse mortality (organ failure and infection, Table 2 ). In this group, four out of the 12 patients developed acute GVHD after second HSCT. However, again no survival benefit was noted in patients with acute GVHD (P ¼ 0.5841, see Supplementary Figure) . There was no observed chronic GVHD in all the patients receiving second SCT.
DISCUSSION
Relapse of a hematological malignancy after an SCT given with intent to cure the disease represents a devastating treatment failure with no ideal treatment options. Whereas there is some consensus that chemotherapy associated with a DLI can prolong survival, only a small minority of patients become long-term survivors. 12, 13 A second SCT may bring a second chance of cure if the second transplant strategy provides a more intensive antileukemic conditioning regimen or a stronger GVL effect. 9 Nevertheless, second SCT carries a high risk of treatment failure, both from relapse and non-relapse mortality. 14 As patients relapsing after SCT show diversity in the aggressiveness and chemosensitivity of their disease, and vary widely in their performance status, second transplants tend to be offered on an individual basis to selected patients, usually those with better disease control and good performance status. An additional factor determining treatment for relapse is dictated by patient preference for either further intensive treatment or palliative measures, and the availability of donor. As a consequence, there are no prospective randomized studies comparing transplant and non-transplant treatments for hematological malignancy relapsing after SCT.
Here, we review our approach to the treatment of relapse after allogeneic SCT in selected patients with at least partial control of their disease who could tolerate a second SCT. Owing to the better outcomes described for late-relapse disease, 2,4 a greater proportion of second transplants were performed in patients relapsing after 6 months of their first SCT (57 vs 34%). The second SCT was performed with a T cell-replete transplant using only CYA as GVHD prophylaxis, in order to enhance the GVL effect over the In this way, it was hoped that a second transplant from the same donor could prolong survival and achieve a second chance of cure of malignancy. While presenting data for relapsed patients not receiving SCT, it must be pointed out that the groups are not matched-there was an inevitable bias in selecting patients for second SCT based on their general fitness, degree of disease control after relapse treatment, patient's choice to undergo further intensive treatment and the availability of donor. Nevertheless, despite more favorable features of the second transplant group, it was disappointing that such patients did not experience an important prolongation of survival with the procedure. This disappointing outcome was shared among all patients regardless of the ability to successfully obtain a CR prior to a second SCT. Patients relapsing early after their first SCT had at best a 3-month survival advantage with a second SCT, offset by inevitably prolonged hospitalization. Comparable to other experience, patients relapsing late after their first SCT generally had a more favorable outcome. 2, 15 The 1-year probability of survival reached 33% for late-relapsed patients undergoing second SCT. Overall, there was 17% survival for late-relapsed patients who were given a second SCT maintained over the 6 years of follow-up in our study. This is the first study to our knowledge of patients receiving a T cell-replete transplant for disease relapsing after an initial TCD SCT. However, our study is limited by the sample size, selection bias for second transplantation and availability of donors for SCT or DLI.
In conclusion, these results indicate that the additional GVL effect from the unmanipulated second SCT was not sufficient to control relapsed disease in most patients who originally received a TCD SCT. A meaningful survival benefit from the second SCT was only observed in late-relapsed patients, and may have been due to selection bias. Based on this 14-year observation, we no longer offer second SCT for patients relapsing within 6 months of transplant, and plan only to further study second SCT for late-relapsed patients in the context of randomized trials comparing SCT with other treatments. It should be noted, however, that these findings specifically relate to the myeloablative regimens used in this patient group. Better outcomes after relapse might be observed in patients who received reduced-intensity conditioning for the first SCT, and more intensive conditioning for the second SCT. Consistent with this observation, recent studies have demonstrated that simply repeating the first SCT maneuver in treating patients with relapsed ALL provides minimal benefit, and that intensifying the conditioning or selecting an alternative donor may confer a greater antileukemic effect. 16 Strategies that include a combination of therapeutic modalities to promote GVL while minimizing risks of toxicity and GVHD may improve outcomes for patients with relapsed disease after SCT. Recent studies have demonstrated the efficacy of azacitidine in the treatment of relapsed AML. Azacitidine upregulates the expression of epigenetically silenced tumor Ags to promote cytotoxic CD8 þ T-cell responses and augment the GVL effect. CR rates of 20-40% have been noted when used as a single agent to treat patients with AML that have relapsed after SCT. Azacitidine also appears well tolerated, and is associated with an expansion of regulatory T cells and low rates of GVHD when used early after SCT. 17 Recently, the combination of azacitidine and DLI as first salvage therapy for relapsed AML or MDS after SCT has been explored and appears safe with low rates of acute GVHD (grades III-IV of 10%). An overall response rate of 30% was observed, with 17% durable CRs (median duration, 777 days), demonstrating the feasibility of combining azacitidine with cellular therapies to augment antileukemic responses while minimizing toxicity. 18 In this context, the combination of epigenetic modifying agents, such as azacitidine, lenalidomide and histone deacetylase inhibitors, with novel cellular therapy to include prophylactic DLIs, natural killer cell infusions and leukemia-specific T cells or leukemia vaccines provides an exciting new avenue for research that may lead to improved treatment of leukemia relapse after allogeneic SCT. 19, 20 
